Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpointBy / 21/12/2023 Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.
